Navigation Links
Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
Date:7/7/2010

BETHESDA, M.D., July 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors.  The funding included $1.75 million in purchases of restricted common stock of the Company (the "Common Stock") by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.  The Company also continued to make progress on restructuring of its balance sheet, through debt conversions and extensions with its largest debt holders.  The new investment by SDS Capital was part of a larger restructuring transaction with SDS.

The $1.75 million in purchases of Common Stock by private investors were made at a price of seventy-five cents ($0.75) per share, with ten percent (10%) warrant coverage.

The restructuring transaction with SDS Capital was undertaken pursuant to a Conversion and Extension Agreement, which included the conversion or extension of all outstanding debt held by SDS, as well as new investment of $250,000 by SDS.  Prior to this Agreement, SDS was the second largest holder of investment debt of the Company.

As previously reported, the Company already entered into an agreement with the Al Rajhi Group in March, 2010, for the extension of all outstanding debt held by Al Rajhi. The Al Rajhi Group is the largest holder of investment debt of the Company.

The Company also entered into a Securities Purchase Agreement with Ms. Linda F. Powers, the Chair of the Company's Board, for the purchase of restricted Common Stock.  Ms. Powers purchased $650,000 of restricted Common Stock at a price per share of seventy-five cents ($0.75), and ten percent (10%) warrant coverage. Accordingly, Ms. Powers purchased 866,667 shares of the Company's restricted Common Stock and warrants for 86,667 shares of Common Stock.  Prior to this purchase, Ms. Powers sold 750,000 shares of her Common Stock.

As part of the Company's ongoing strengthening of its balance sheet, the Company is using the proceeds of the sale of stock to Ms. Powers to pay down certain outstanding trade payables.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has two broad platform technologies:  dendritic cell-based vaccines and therapeutic antibodies.  The Company is focusing on development of its dendritic cell vaccines.  The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in GBM.  The trial remains open but is not currently enrolling patients.  As part of the debt restructuring and ongoing fundraising activities, the Company expects to resume enrollment in this GBM trial later in the summer.  The Company also received clearance from the FDA some time ago for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and uncertainties about whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
2. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
3. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
4. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
5. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
6. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
7. Oncothyreon to present at Invest Northwest 2009
8. Sirius Genomics to Present at Invest Northwest Conference
9. Northwest Biotherapeutics Secures $700,000 Equity Financing
10. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
11. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation President ... and Astronomy, has been selected for membership in ARCS Alumni Hall of Fame ... Prize in Fundamental physics for the discovery of the accelerating expansion of the universe, ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):